Halozyme Therapeutics HALO Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's invested capital?
- Halozyme Therapeutics (HALO) reported invested capital of $2.08B in Q1 2026.
- How has Halozyme Therapeutics's invested capital changed year-over-year?
- Halozyme Therapeutics's invested capital increased by 13.1% year-over-year, from $1.84B to $2.08B.
- What is the long-term trend for Halozyme Therapeutics's invested capital?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's invested capital has grown at a 38.8% compound annual growth rate (CAGR), from $404.94M to $2.09B.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).